Clinical Trial Update: Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 randomized placebo-controlled trial of IVIg in glycine receptor antibody–positive Stiff-Person Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stiff-person Syndrome

Drugs mentioned

• IVIG (intravenous immunoglobulin)

Snippet

Sponsor: Mayo Clinic | Conditions: Stiff-Person Syndrome | Phase 3 | Status: WITHDRAWN